New Haven, Connecticut
Summary
This clinical-stage biotechnology company focuses on developing targeted protein degradation therapeutics using a proprietary platform. Their mission is to improve the lives of patients with serious diseases, particularly in oncology and neuroscience, by creating transformative medicines that challenge traditional drug discovery limits. The company emphasizes innovation, collaboration with leading drug companies, and a commitment to patient advocacy.
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
11.2 years — Since Oct 2013
Web Hosting
Platform
E-Mail Provider
Microsoft Office 365
NAICS Code
325414
SIC 4 Digit Code
2836
SIC 2 Digit Code
28
Industry
1. Biotechnology
2. Biological Product (except Diagnostic) Manufacturing
Vendor
Source
Apple
TXT Record
Atlassian
TXT Record
DocuSign
TXT Record
TXT Record
Nintex
TXT Record
Smartsheet
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|